The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract.

Deficiency of apoptosis is a hallmark of chronic lymphocytic leukemia (CLL) cells. M2Yn is a natural extract from plants of central Asia, identified for its antiangiogenic properties and its ability to block the migration of malignant cells. Here, we report that in vitro treatment of cells derived from CLL patients with M2Yn results in internucleosomal DNA fragmentation, phosphatidylserine externalization, mitochondrial membrane depolarization, caspase-3 activation and cleavage of the caspase substrate PARP-1. The extents of these effects depend on the patients and are mostly comparable to those of flavopiridol or hyperforin, two known plant-derived apoptosis inducers of CLL cells. M2Yn does not modulate Mcl-1 expression, while downregulation of this antiapoptotic protein is involved in the action of flavopiridol. By contrast, M2Yn, like hyperforin, upregulates the Noxa protein, possibly by inhibiting proteasomal activity. This BH3-only protein is known to trigger the activation of the pro-apoptotic protein Bak through displacement of the Mcl-1/Bak complex at the mitochondrial membrane, as actually observed here in M2Yn-treated cells. Our data, therefore, show that M2Yn can induce the caspase-dependent mitochondrial pathway of apoptosis in CLL cells via a mechanism resembling that of hyperforin. Our data also confirm that the BH3-only protein Noxa is a relevant target for CLL therapy.

[1]  Di Chen,et al.  Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. , 2005, Biochemical pharmacology.

[2]  J. Kolb,et al.  Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol , 2009, Leukemia.

[3]  T. Riss,et al.  Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format. , 2009, Analytical biochemistry.

[4]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[5]  M. Keating,et al.  Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.

[6]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[7]  M. Caligiuri,et al.  Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity , 2007, Clinical Cancer Research.

[8]  M. Rothley,et al.  Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor‐induced lymphangiogenesis in vivo , 2009, International journal of cancer.

[9]  S. Malek,et al.  Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.

[10]  Y. Naït-Si,et al.  Effect of eluent pH on the HPLC-UV analysis of hyperforin from St. John's Wort (Hypericum perforatum L.). , 2006, Phytochemical analysis : PCA.

[11]  G. Cohen,et al.  Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa , 2007, Leukemia.

[12]  P. Hersey,et al.  Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells , 2006, Anti-cancer drugs.

[13]  J. Byrd,et al.  Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia , 2006, Cancer.

[14]  J. Kolb,et al.  Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. , 2003, Current drug targets. Cardiovascular & haematological disorders.

[15]  John Calvin Reed,et al.  Protein Kinase Inhibitors Flavopiridol and 7-hydroxy-staurosporine Down-regulate Antiapoptosis Proteins in B-cell Chronic Lymphocytic Leukemia , 2022 .

[16]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[17]  L. Pleyer,et al.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches , 2009, Nature Reviews Clinical Oncology.

[18]  S. Aiyar,et al.  TMS, a chemically modified herbal derivative of Resveratrol, induces cell death by targeting Bax , 2010, Breast Cancer Research and Treatment.

[19]  M. Blagosklonny Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions , 2004, Cell cycle.

[20]  M. Grever,et al.  Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. , 1998, Blood.

[21]  Derek A. West,et al.  The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. , 2009, Blood.

[22]  John Calvin Reed,et al.  Triterpenoids Display Single Agent Anti-tumor Activity in a Transgenic Mouse Model of Chronic Lymphocytic Leukemia and Small B Cell Lymphoma , 2007, PloS one.

[23]  W. Plunkett,et al.  Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. , 2005, Blood.

[24]  Chun-ching Lin,et al.  Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. , 2005, Life sciences.

[25]  G. Packham,et al.  Bodyguards and assassins: Bcl‐2 family proteins and apoptosis control in chronic lymphocytic leukaemia , 2005, Immunology.

[26]  A. Faussat,et al.  4-arylcoumarin analogues of combretastatins stimulate apoptosis of leukemic cells from chronic lymphocytic leukemia patients. , 2008, Experimental hematology.

[27]  R. Mohammad,et al.  Analysis of resveratrol‐induced apoptosis in human B‐cell chronic leukaemia , 2002, British journal of haematology.

[28]  M. Grever,et al.  Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. , 2005, Leukemia research.

[29]  Lin Chen,et al.  Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.

[30]  S. Parodi,et al.  Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic , 2009, Cancer biology & therapy.

[31]  Thomas S. Lin,et al.  Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. , 2009, Blood.

[32]  A. Ballestrero,et al.  Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. , 2005, Blood.

[33]  C. Peschel,et al.  Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells , 2004, Leukemia.

[34]  F. Ajchenbaum‐Cymbalista,et al.  Flavopiridol downregulates the expression of both the inducible NO synthase and p27kip1 in malignant cells from B-cell chronic lymphocytic leukemia , 2003, Leukemia.

[35]  H. Xin,et al.  Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. , 2006, Cancer research.

[36]  S. Shankar,et al.  Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. , 2007, Frontiers in bioscience : a journal and virtual library.

[37]  B. Cheson,et al.  Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. , 2009, Blood.

[38]  M. Keating,et al.  Chemoimmunotherapy of chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.

[39]  F. Ajchenbaum‐Cymbalista,et al.  Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. , 2004, Blood.

[40]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[41]  Liang Xu,et al.  Natural Proteasome Inhibitor Celastrol Suppresses Androgen-Independent Prostate Cancer Progression by Modulating Apoptotic Proteins and NF-kappaB , 2010, PloS one.

[42]  A. Faussat,et al.  Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia , 2006, Leukemia.

[43]  Lisa S. Chen,et al.  Mcl-1: the 1 in CLL. , 2008, Blood.

[44]  Annelieke Jaspers,et al.  Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. , 2007, Blood.

[45]  M. Hendrix,et al.  Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. , 2005, Cancer research.